Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 0.72 |
| ▸ | NPC1 | O15118 | 13/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.70 |
| ▸ | RELA | Q04206 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.65 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5959967 | 0.89 | SMN1; SMN2 (0.85) | RAB9ANPC1SMN1; SMN2MAPTNR1H4 | |
| SCHEMBL28651531 | 0.84 | NR1H4 (0.78) | RAB9ANPC1SMN1; SMN2MAPTNR1H4 | |
| SCHEMBL28637707 | 0.84 | NR1H4 (0.78) | RAB9ANPC1SMN1; SMN2MAPTNR1H4 | |
| SCHEMBL27001834 | 0.82 | NR1H4 (0.70) | RAB9ANPC1SMN1; SMN2MAPTNR1H4 | |
| SCHEMBL26095552 | 0.82 | NR1H4 (0.70) | RAB9ANPC1SMN1; SMN2MAPTNR1H4 | |
| SCHEMBL27001784 | 0.82 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 | |
| SCHEMBL3736895 | 0.82 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 | |
| SCHEMBL3737008 | 0.81 | SMN1; SMN2 (1.00) | RAB9ANPC1SMN1; SMN2MAPTNR1H4 | |
| SCHEMBL10495613 | 0.80 | NR1H4 (0.77) | RAB9ANPC1SMN1; SMN2MAPTNR1H4 | |
| SCHEMBL3745631 | 0.80 | SMN1; SMN2 (0.66) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | claimed |
| US-20100010001-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-14 | — | — | US | disclosed |
| US-20100010001-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-14 | — | — | US | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | RAB9A 1813/4885NPC1 941/4885SMN1; SMN2 1279/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | RAB9A 1813/4885NPC1 941/4885SMN1; SMN2 1279/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | RAB9A 1813/4885NPC1 941/4885SMN1; SMN2 1279/4885 |
| US-20100010001-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | S1PR1, S1PR3, S1PR4 | RAB9A 2501/4885NPC1 1399/4885SMN1; SMN2 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.